Producer

Aptar Pharma

ATRHQ US · Crystal Lake, Illinoiswebsite ↗

American drug delivery and packaging company (NYSE: ATR, HQ Crystal Lake IL; ~$3.5B revenue); Aptar Pharma division produces drug delivery devices and components including injectable drug delivery systems, needle-free injection components, and parenteral packaging. For IV bag applications, Aptar supplies injection site components and additive port systems. Aptar also produces metered-dose inhaler (MDI) valves for asthma inhalers (a major product line), nasal spray pumps, and eye dropper closures. The same Aptar company that makes the pumping mechanism in your nasal allergy spray also supplies components for IV bag injection ports.

2

Inputs supplied

2

Goods downstream

2

Facilities

0

Stories

What they make

2 inputs Aptar Pharma supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where it shows up

Goods downstream

Essential goods that depend on something Aptar Pharma makes, pick one to see the full supply chain.

What else they do

Business segments

The company's full revenue map, where this supply-chain role fits within their broader business.

  • Pharmaceutical Drug Delivery Devices

    38%
  • Beauty, Home & Personal Care (Consumer)

    42%
  • Food & Beverage Dispensing

    20%

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

  • Did you know2023

    Aptar produces the dispensing technology across three completely unrelated consumer and healthcare supply chains: (1) Consumer cosmetics — the pump dispenser on your hand lotion, the fine mist nozzle on your fragrance, and the sprayer on your household cleaner are Aptar products, branded as Natür, Criquet, or Stella pump platforms; (2) Pharmaceutical inhaler valves — the Aptar MDI valve in an AstraZeneca Symbicort or Boehringer Ingelheim Spiriva meters 50-100 mcg of drug per actuation into a patient's lungs; (3) Emergency medicine — Aptar produces the Narcan (naloxone) intranasal delivery device for opioid overdose reversal; the same nasal spray pump technology in allergy medication (Flonase, Nasonex) is used to deliver naloxone nasally to reverse opioid overdose, without requiring injection training. The opioid crisis response (scaling up naloxone access via intranasal route) depended on Aptar's drug delivery technology being available, affordable, and FDA-qualified. A consumer cosmetics pump manufacturer is structurally embedded in emergency opioid overdose response infrastructure.

    AptarGroup Pharma Division
  • Origin2023

    AptarGroup was formed through a 1992 demerger from Albert Fischer Group (a German packaging conglomerate), combining what had been separate aerosol and dispensing divisions from the European packaging industry. The combined Aptar entity focused on precision dispensing systems across consumer and pharmaceutical applications. Over 30 years, Aptar built dominant positions in both segments by sharing underlying precision pump and valve manufacturing expertise: the tolerance requirements for a pharmaceutical metering valve (±5-15% dose accuracy, compatible with drug formulations) and a consumer fragrance spray pump (consistent particle size distribution, elegant actuation feel) are technically similar even though regulatory standards differ by orders of magnitude. A luxury perfume brand and a pharmaceutical company both need Aptar's pump technology — one for aesthetic spray consistency and one for patient safety dosing. Aptar's cross-industry position means its R&D in one segment informs the other; vaccine injection advances feed back into precision consumer aerosol design.

    AptarGroup, Inc.